Susan Orr is a distinguished Board Member at RETINA GLOBAL, where she leverages her extensive expertise in ophthalmology and drug development to drive innovation and strategic growth within the organization. With a robust background in both the medical and business sectors, Susan is adept at...
Susan Orr is a distinguished Board Member at RETINA GLOBAL, where she leverages her extensive expertise in ophthalmology and drug development to drive innovation and strategic growth within the organization. With a robust background in both the medical and business sectors, Susan is adept at identifying promising ophthalmic therapeutic and medical device product candidates, guiding them from conception through to market launch. Her leadership is characterized by a transformative approach, fostering operational success in both public and private enterprises.
At RETINA GLOBAL, Susan is currently involved in several key projects aimed at advancing cutting-edge treatments for retinal diseases. Her strategic oversight in regulatory submissions ensures compliance with FDA standards, facilitating smoother pathways for product approval. Additionally, her experience in pharmacology and infectious diseases positions her as a vital contributor to the development of therapies that address complex ocular conditions, particularly in patients with comorbidities such as diabetes.
Susan's proven track record in building strategic alliances and scaling organizations is instrumental in RETINA GLOBAL's mission to enhance patient outcomes through innovative solutions. Her leadership style emphasizes collaboration and cross-functional teamwork, enabling the company to build new capabilities and adapt to the rapidly evolving landscape of ophthalmic care. As a thought leader in the field, Susan continues to influence the direction of ophthalmic research and development, ensuring that RETINA GLOBAL remains at the forefront of advancements in eye health.
